Ignite Creation Date:
2025-12-24 @ 4:27 PM
Ignite Modification Date:
2026-01-20 @ 11:28 PM
Study NCT ID:
NCT05325866
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-10-01
First Post:
2022-04-06
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
Sponsor:
Amgen
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Solid Tumors | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Epithelial solid tumors with fibroblast growth factor receptor 2b overexpression | View |
| None | FGFR2b | View |
| None | Head and neck squamous cell carcinoma | View |
| None | Triple-negative breast cancer | View |
| None | Intrahepatic cholangiocarcinoma | View |
| None | Lung adenocarcinoma | View |
| None | Ovarian epithelial carcinoma | View |
| None | Endometrial adenocarcinoma | View |
| None | Cervical carcinoma | View |
| None | Bemarituzumab | View |
| None | AMG 552 | View |
| None | Other solid tumors | View |